BR112014002373A2 - mutações no gene do receptor do fator de crescimento epidermal - Google Patents

mutações no gene do receptor do fator de crescimento epidermal

Info

Publication number
BR112014002373A2
BR112014002373A2 BR112014002373A BR112014002373A BR112014002373A2 BR 112014002373 A2 BR112014002373 A2 BR 112014002373A2 BR 112014002373 A BR112014002373 A BR 112014002373A BR 112014002373 A BR112014002373 A BR 112014002373A BR 112014002373 A2 BR112014002373 A2 BR 112014002373A2
Authority
BR
Brazil
Prior art keywords
growth factor
factor receptor
epidermal growth
receptor gene
therapy regimen
Prior art date
Application number
BR112014002373A
Other languages
English (en)
Portuguese (pt)
Inventor
Dalmases Massegú Alba
Rovira Guerin Ana
Bellosillo Paricio Beatriz
Montagut Viladot Clara
Albanell Mestres Joan
Original Assignee
Fundació Inst Mar D'investigacions Mèdiques (Imim)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Inst Mar D'investigacions Mèdiques (Imim) filed Critical Fundació Inst Mar D'investigacions Mèdiques (Imim)
Publication of BR112014002373A2 publication Critical patent/BR112014002373A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112014002373A 2011-08-03 2012-08-02 mutações no gene do receptor do fator de crescimento epidermal BR112014002373A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382270A EP2554551A1 (en) 2011-08-03 2011-08-03 Mutations in the epidermal growth factor receptor gene
PCT/EP2012/065090 WO2013017645A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
BR112014002373A2 true BR112014002373A2 (pt) 2017-02-21

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002373A BR112014002373A2 (pt) 2011-08-03 2012-08-02 mutações no gene do receptor do fator de crescimento epidermal

Country Status (12)

Country Link
US (1) US9765399B2 (cg-RX-API-DMAC7.html)
EP (3) EP2554551A1 (cg-RX-API-DMAC7.html)
JP (1) JP6149034B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140072035A (cg-RX-API-DMAC7.html)
CN (1) CN103717616B (cg-RX-API-DMAC7.html)
AU (1) AU2012292024A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014002373A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842270C (cg-RX-API-DMAC7.html)
ES (1) ES2556468T3 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN00570A (cg-RX-API-DMAC7.html)
RU (1) RU2014107908A (cg-RX-API-DMAC7.html)
WO (1) WO2013017645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2015175705A1 (en) 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
JP6905464B2 (ja) * 2014-07-28 2021-07-21 フンダシオ インスティトゥ マー ディンヴェスティガシオンズ メディクー(イーエメイーエメ) 上皮増殖因子受容体遺伝子の細胞外ドメインiii内の変異
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
EP3286219A1 (en) * 2015-04-24 2018-02-28 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
RU2626682C1 (ru) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558753A1 (en) 2004-03-01 2005-09-15 University Of Chicago Polymorphisms in the epidermal growth factor receptor gene promoter
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2601936C (en) * 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
JP5596975B2 (ja) * 2006-10-26 2014-10-01 ジェネンテック, インコーポレイテッド 腫瘍と関連している遺伝的変異
CA2675362A1 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
EP3216874A1 (en) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options

Also Published As

Publication number Publication date
CA2842270A1 (en) 2013-02-07
RU2014107908A (ru) 2015-09-10
EP2554551A1 (en) 2013-02-06
AU2012292024A1 (en) 2014-02-27
WO2013017645A1 (en) 2013-02-07
JP2014521342A (ja) 2014-08-28
KR20140072035A (ko) 2014-06-12
EP2739648A1 (en) 2014-06-11
US9765399B2 (en) 2017-09-19
US20140170662A1 (en) 2014-06-19
CN103717616A (zh) 2014-04-09
JP6149034B2 (ja) 2017-06-14
EP2739648B1 (en) 2015-09-16
CN103717616B (zh) 2016-06-29
ES2556468T3 (es) 2016-01-18
EP2995623A1 (en) 2016-03-16
CA2842270C (en) 2019-10-29
IN2014CN00570A (cg-RX-API-DMAC7.html) 2015-04-03

Similar Documents

Publication Publication Date Title
IN2014CN00570A (cg-RX-API-DMAC7.html)
MX364410B (es) Metodo para detectar nucleosomas que contienen nucleotidos.
NZ621733A (en) Lung cancer biomarkers and uses thereof
CA3257616A1 (en) Measurement of protein expression using reagents with barcoded oligonucleotide sequences
WO2013022786A3 (en) Microrna biomarkers
ES2720999T3 (es) Método y sistema para seleccionar un fármaco sobre la base de la información del daño de proteína individual para prevenir los efectos secundarios de un fármaco
WO2012138783A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
GB2488700B (en) Methods for monitoring disease conditions by analysis of the full repertoire of CDR3 sequences of an individual
HUE058723T2 (hu) Molekuláris analitok digitális elemzése egyetlen molekula kimutatásával
BR112013015508A2 (pt) molécula de anticorpo isolada para il-18 humana, composição, uso de uma molécula de anticorpo, molécula de ácido nucleico isolada, célula hospedeira, e, métodos para produzir um anticorpo e para medir il-18
JP2011217747A5 (cg-RX-API-DMAC7.html)
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
WO2012074904A3 (en) Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
BR112014021993B8 (pt) "métodos para detecção de uma variação de nucleotídeo em uma sequência de ácido nucleico alvo através de um ensaio de ptoce"
BR112012017532A2 (pt) "método para determinar um polipeptídeo com uma sequência de aminoácidos mutante, para produzir um poliptedo e uma imunoglobulina"
BR112015003724A2 (pt) polipeptídeo isolado, composição, uso de uma composição, polinucleotídeo isolado, constructo de ácido nucleico ou vetor de expressão, célula hospedeira recombinante, e, métodos de produção de um polipeptídeo e de produção de uma proteína.
BR112015001102A2 (pt) método de detecção de câncer, droga ou kit e método de seleção de droga terapêutica
BR112012021590A2 (pt) detecção de capacitância em ensaio eletroquímico
BR112015019567A8 (pt) inibidor de wnt, seu uso e métodos para prognosticar sensibilidade ao mesmo, e composição farmacêutica
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
WO2017053792A8 (en) Method for determining the in vivo comparability of biologic drug and a reference drug
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements